A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1307-1309

  Shah, Keerti V ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

condyloma; HPV; HPV 6 11; immunization; pregnancy; respiratory papillomas

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANTIBODY RESPONSE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONDYLOMA; DISEASE ASSOCIATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; INCIDENCE; INFECTION RISK; JUVENILE ONSET LARYNGEAL PAPILLOMA; LARYNX PAPILLOMATOSIS; MATERNAL CARE; PAPILLOMAVIRUS INFECTION; PASSIVE IMMUNIZATION; PREGNANCY DISORDER; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

CONDYLOMA; HPV; HPV 6/11; IMMUNIZATION; PREGNANCY; RESPIRATORY PAPILLOMAS;

CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RESPIRATORY TRACT INFECTIONS;

EID: 84898895848     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit611     Document Type: Review

References (17)

1. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012; 30:6016-9
2. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121: 1386-91
3. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: A longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004; 114(11 Pt 2 suppl 104):1-23
4. Hajek EF. Contribution to the etiology of laryngeal papilloma in children. J Laryngol Otol 1956; 70:166-8
5. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile-And adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci U S A1982; 79:5425-9
6. Gissmann L, Diehl V, Schultz-Coulon HJ, zur Hausen H. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 1982; 44:393-400
7. Shah KV, Unger ER, Derkay CS, Sternberg M. Recurrent respiratory papillomatosis: Bright prospects for vaccine-based prevention. Papillomavirus Rep 2005; 16:333-8
8. Carter JJ, Wipf GC, Hagensee ME, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995; 172:11-8
9. Maloney EM, Unger ER, Tucker RA, et al. Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2006; 132:711-5
10. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645-52
11. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/ 11/16/18 vaccine on all HPV-Associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39
12. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7:230-8
13. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/ 16/18 vaccine: A combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114:1179-88
14. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-Associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175-201
15. Matys K, Mallary S, Bautista O, et al. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol 2012; 19:881-5
16. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health And Nutrition Examination Survey, 2003-2006: Opportunity to measure HPV vaccine impact? J Infect Dis 2011; 204:562-5
17. Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol 2012; 55:474-86.